SCHEMBL31666071

SCHEMBL31666071

CCn1c(CNC(=O)c2nc3cc[nH]c3nc2N)[n+](C)c2ccccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD5 P21918 1/20 0.38
SCNN1A P37088 1/20 0.38
SCNN1B P51168 1/20 0.38
SCNN1G P51170 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
HTT P42858 3/20 0.36
MAPK1 P28482 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
KDM4E B2RXH2 2/20 0.34
RAB9A P51151 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TP53 P04637 2/20 0.34
MAPT P10636 2/20 0.34
POLB P06746 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20209215 1.00 DRD5 (0.38) DRD5SCNN1ASCNN1BSCNN1GHRH3
Formic Acid SCHEMBL21460840 0.96 DRD5 (0.35) DRD5SCNN1ASCNN1BSCNN1GHRH3
SCHEMBL31666053 0.90 CD38 (0.39) HTTKDM4EMEN1KMT2ATP53
SCHEMBL21460659 0.90 CD38 (0.39) HTTKDM4EMEN1KMT2ATP53
SCHEMBL20209000 0.88 HRH3 (0.44) DRD5SCNN1ASCNN1BSCNN1GHRH3
SCHEMBL21460594 0.88 DRD5 (0.40) DRD5SCNN1ASCNN1BSCNN1GHRH3
Hydrochloric Acid SCHEMBL21460626 0.87 DRD5 (0.42) DRD5SCNN1ASCNN1BSCNN1GHRH3
Formic Acid SCHEMBL21460761 0.86 CD38 (0.36) TP53MAPTPOLBCYP1A2CD38
SCHEMBL21460685 0.86 DRD5 (0.40) DRD5SCNN1ASCNN1BSCNN1GHRH3
SCHEMBL21460611 0.85 DRD5 (0.39) DRD5SCNN1ASCNN1BSCNN1GHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371436-B2 Substituted benzodiazoliums as ENaC inhibitors Enterprise Therapeutics Limited (GB) 2025-07-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371436-B2 Substituted benzodiazoliums as ENaC inhibitors NHERF1, SCNN1B, SCNN1A DRD5 3780/4885SCNN1A 3/4885SCNN1B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.